Belizatinib
Belizatinib (TSR-011) is an orally active, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase.
Product Specifications
CAS Number
[1357920-84-3]
Product Name Alternative
TSR-011
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Anaplastic lymphoma kinase (ALK) ; Trk Receptor
Type
Reference compound
Related Pathways
Neuronal Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Belizatinib.html
Concentration
10mM
Purity
99.62
Solubility
DMSO : ≥ 300 mg/mL
Smiles
O=C(NC1=NC2=CC=C(CN3CCC(C(C)(O)C)CC3)C=C2N1[C@H]4CC[C@@H](C(NC(C)C)=O)CC4)C5=CC=C(F)C=C5
Molecular Formula
C33H44FN5O3
Molecular Weight
577.73
Precautions
H302, H315, H319, H335
References & Citations
[1]Sullivan I, et al. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016 Jan;8 (1) :32-47.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
TrkA; TrkB; TrkC
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Human Receptor I for the Fc region of immunoglobulin G, FcγRI ELISA Kit
